FebriDx Antimicrobial Resistance (AMR) Screening Test
FebriDx Antimicrobial Resistance (AMR) Screening Test
Test platform designed & manufactured by Atomo; Branded & Distributed by Lumos
Sold in Europe and under review with the US FDA
authorised to identify and differentiate viral from bacterial acute respiratory infection. With 99% accuracy, this test has reduced antibiotic prescriptions by 80%, leading to better efficiencies and lower costs.

Finished rapid test products are commercialised under Atomo's own brand or under private labels via partners and regional distributors. We hold regulatory approvals including CE Mark in the EU/ UK, Australian TGA, and the World Health Organization with FDA approvals pending.